BioAge Labs
BIOAPhase 2BioAge Labs harnesses aging biology to develop novel therapies for obesity and metabolic diseases through their proprietary multi-omics discovery platform. Their lead candidate BGE-102 targets NLRP3-mediated inflammation, while their APJ program aims to mimic exercise benefits for obesity treatment. The company recently completed a $115 million public offering and trades on NASDAQ under ticker BIOA.
BIOA · Stock Price
Historical price data
AI Company Overview
BioAge Labs harnesses aging biology to develop novel therapies for obesity and metabolic diseases through their proprietary multi-omics discovery platform. Their lead candidate BGE-102 targets NLRP3-mediated inflammation, while their APJ program aims to mimic exercise benefits for obesity treatment. The company recently completed a $115 million public offering and trades on NASDAQ under ticker BIOA.
Technology Platform
Human-first discovery platform that analyzes proprietary multi-omics data captured over decades to identify molecular mediators of aging and disease, enabling the development of therapies targeting metabolic aging pathways.
Pipeline Snapshot
44 drugs in pipeline
| Drug | Indication | Stage |
|---|---|---|
| BGE-117 | Anemia | Phase 2 |
| BGE-175 | Covid19 | Phase 2 |
| BGE-117, 4mg + BGE-117, 12mg | Acute Posthemorrhagic Anemia | Phase 2 |
| Azelaprag | Healthy Volunteer Study | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
BioAge competes with NLRP3 inhibitor developers like Roche/Inflazome, major obesity players including Novo Nordisk and Eli Lilly, and aging biology companies like Altos Labs and Unity Biotechnology. The company differentiates through its human-first discovery approach targeting the specific intersection of aging and metabolic health.
Company Info
Trading
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile